These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 19372852)

  • 1. Clinical trials for heavily pretreated patients: update in 2006.
    Katlama C; Ghosn J
    Curr Opin HIV AIDS; 2006 Nov; 1(6):495-501. PubMed ID: 19372852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to newly approved and investigational protease inhibitors.
    De Luca A
    Curr Opin HIV AIDS; 2007 Mar; 2(2):130-6. PubMed ID: 19372878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of the highly experienced patient.
    Hicks C
    Curr Opin HIV AIDS; 2006 Sep; 1(5):424-9. PubMed ID: 19372842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Issues in the design of trials comparing management strategies for heavily pretreated patients.
    Phillips AN; Cohen C; Lundgren JD
    Curr Opin HIV AIDS; 2006 Nov; 1(6):476-81. PubMed ID: 19372849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New targets in antiretroviral therapy 2006.
    Wilkin A; Feinberg J
    Curr Opin HIV AIDS; 2006 Sep; 1(5):437-41. PubMed ID: 19372844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.
    Hughes CA; Robinson L; Tseng A; MacArthur RD
    Expert Opin Pharmacother; 2009 Oct; 10(15):2445-66. PubMed ID: 19678794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on HIV-1 viral load blips.
    Nettles RE; Kieffer TL
    Curr Opin HIV AIDS; 2006 Mar; 1(2):157-61. PubMed ID: 19372801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV.
    Kiser JJ
    Curr Opin HIV AIDS; 2008 May; 3(3):330-41. PubMed ID: 19372987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining protease inhibitors with new drug classes in treatment-experienced patients.
    Walmsley S
    Curr Opin HIV AIDS; 2008 Nov; 3(6):647-52. PubMed ID: 19373037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in HIV drug resistance.
    Cane PA
    J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i37-40. PubMed ID: 19675018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical approach to drug resistance interpretation: expert advice.
    Clotet B; Paredes R
    Curr Opin HIV AIDS; 2007 Mar; 2(2):145-9. PubMed ID: 19372880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of human immunodeficiency virus as a target for antiretroviral therapy.
    Semenova EA; Johnson AA; Marchand C; Pommier Y
    Curr Opin HIV AIDS; 2006 Sep; 1(5):380-7. PubMed ID: 19372837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy?
    Winston A; Khoo S
    Curr Opin HIV AIDS; 2008 Nov; 3(6):608-11. PubMed ID: 19373031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.
    Salgado M; Toro C; Simón A; Garrido C; Blanco F; Soriano V; Rodés B
    J Clin Virol; 2009 Oct; 46(2):173-5. PubMed ID: 19625211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug resistance mutations and the cellular immune response: a valuable synergy for the development of novel immune therapies.
    Chomont N; Trautmann L; Routy JP; Sékaly RP
    Curr Opin HIV AIDS; 2007 Mar; 2(2):116-22. PubMed ID: 19372876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment interruption in advanced failing patients.
    Staszewski S
    Curr Opin HIV AIDS; 2007 Jan; 2(1):39-45. PubMed ID: 19372864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approaches to the design of HIV protease inhibitors with improved resistance profiles.
    Gulnik SV; Eissenstat M
    Curr Opin HIV AIDS; 2008 Nov; 3(6):633-41. PubMed ID: 19373035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV coreceptor CXCR4 antagonists.
    Schols D
    Curr Opin HIV AIDS; 2006 Sep; 1(5):361-6. PubMed ID: 19372834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.